GapMind for catabolism of small carbon sources

 

myo-inositol catabolism in Epibacterium ulvae U95

Best path

PGA1_c07300, PGA1_c07310, PGA1_c07320, iolG, iolE, iolD, iolB, iolC, iolJ, mmsA, tpi

Rules

Overview: Myo-inositol degradation in GapMind is based on MetaCyc pathways myo-inositol degradation I via inosose dehydratase (link) and pathway II inosose dehydrogenase (link).

29 steps (20 with candidates)

Or see definitions of steps

Step Description Best candidate 2nd candidate
PGA1_c07300 myo-inositol ABC transport, substrate-binding component CV091_RS18680
PGA1_c07310 myo-inositol ABC transporter, permease component CV091_RS18685 CV091_RS09515
PGA1_c07320 myo-inositol ABC transporter, ATPase component CV091_RS18690 CV091_RS04375
iolG myo-inositol 2-dehydrogenase CV091_RS14400 CV091_RS18660
iolE scyllo-inosose 2-dehydratase CV091_RS18665
iolD 3D-(3,5/4)-trihydroxycyclohexane-1,2-dione hydrolase CV091_RS18655
iolB 5-deoxy-D-glucuronate isomerase CV091_RS18645 CV091_RS14395
iolC 5-dehydro-2-deoxy-D-gluconate kinase CV091_RS18650
iolJ 5-dehydro-2-deoxyphosphogluconate aldolase CV091_RS18640 CV091_RS12880
mmsA malonate-semialdehyde dehydrogenase CV091_RS03700 CV091_RS05715
tpi triose-phosphate isomerase CV091_RS01450 CV091_RS03970
Alternative steps:
eda 2-keto-3-deoxygluconate 6-phosphate aldolase CV091_RS12805 CV091_RS08690
HMIT myo-inositol:H+ symporter
iatA myo-inositol ABC transporter, ATPase component IatA CV091_RS09525 CV091_RS04390
iatP myo-inositol ABC transporter, permease component IatP CV091_RS03805 CV091_RS04370
ibpA myo-inositol ABC transporter, substrate-binding component IbpA
iolF myo-inositol:H+ symporter
iolM 2-inosose 4-dehydrogenase
iolN 2,4-diketo-inositol hydratase
iolO 5-dehydro-L-gluconate epimerase
iolT myo-inositol:H+ symporter
kdgK 2-keto-3-deoxygluconate kinase CV091_RS09550 CV091_RS03830
PS417_11885 myo-inositol ABC transporter, substrate-binding component CV091_RS09530
PS417_11890 myo-inositol ABC transporter, ATPase component CV091_RS09525 CV091_RS04390
PS417_11895 myo-inositol ABC transporter, permease component CV091_RS03805 CV091_RS09520
SMIT1 myo-inositol:Na+ symporter
uxaE D-tagaturonate epimerase
uxuA D-mannonate dehydratase CV091_RS17315 CV091_RS17175
uxuB D-mannonate dehydrogenase CV091_RS12705 CV091_RS13430

Confidence: high confidence medium confidence low confidence
transporter – transporters and PTS systems are shaded because predicting their specificity is particularly challenging.

This GapMind analysis is from Sep 24 2021. The underlying query database was built on Sep 17 2021.

Links

Downloads

Related tools

About GapMind

Each pathway is defined by a set of rules based on individual steps or genes. Candidates for each step are identified by using ublast (a fast alternative to protein BLAST) against a database of manually-curated proteins (most of which are experimentally characterized) or by using HMMer with enzyme models (usually from TIGRFam). Ublast hits may be split across two different proteins.

A candidate for a step is "high confidence" if either:

where "other" refers to the best ublast hit to a sequence that is not annotated as performing this step (and is not "ignored").

Otherwise, a candidate is "medium confidence" if either:

Other blast hits with at least 50% coverage are "low confidence."

Steps with no high- or medium-confidence candidates may be considered "gaps." For the typical bacterium that can make all 20 amino acids, there are 1-2 gaps in amino acid biosynthesis pathways. For diverse bacteria and archaea that can utilize a carbon source, there is a complete high-confidence catabolic pathway (including a transporter) just 38% of the time, and there is a complete medium-confidence pathway 63% of the time. Gaps may be due to:

GapMind relies on the predicted proteins in the genome and does not search the six-frame translation. In most cases, you can search the six-frame translation by clicking on links to Curated BLAST for each step definition (in the per-step page).

For more information, see:

If you notice any errors or omissions in the step descriptions, or any questionable results, please let us know

by Morgan Price, Arkin group, Lawrence Berkeley National Laboratory